Nanomedicine: Innovative applications in medicine;Nanomedizin: Innovative Anwendungen in der Medizin

HNO

Volumn 61, Issue 3, 2013, Pages 197-201

  Alexiou, C ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cancer therapy; Magnetic drug targeting; Nanomedicine; Nanotechnology; Theranostics

Indexed keywords

EID: 84874808250     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-012-2562-6     Document Type: Article

References (39)

1. Alexiou C, Arnold W, Klein R et al (2000) Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60: 6641-6648.
2. Alexiou C, Diehl D, Henninger P et al (2006) A high field gradient magnet for magnetic drug targeting. IEEE Trans Appl Supercond 16: 1527-1530.
3. Alexiou C, Jurgons R, Schmid R et al (2003) Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 11: 139-149.
4. Alexiou C, Jurgons R, Schmid R et al (2005) Magnetisches Drug Targeting: ein neuer Ansatz in der lokoregionären Tumortherapie mit Chemotherapeutika - Tierexperimentelle Untersuchungen. HNO 53: 618-622.
5. Alexiou C, Jurgons R, Seliger C et al (2006) Medical applications of magnetic nanoparticles. J Nanosci Nanotechnol 6: 2762-2768.
6. Alexiou C, Jurgons R, Seliger C et al (2007) Delivery of Superparamagnetic Nanoparticles for local chemotherapy after intraarterial infusion and magnetic targeting. Anticancer Res 27: 2019-2022.
7. Alexiou C, Schmid R, Jurgons R et al (2006) Targeting cancer cells: magnetic nanoparticles as drug carrier. Eur Biophys J 35: 446-450.
8. Alexiou C, Schmidt A, Klein RJ et al (2002) Magnetic drug targeting: biodistribution and dependency on magnetic field strength. J Magn Magn Mater 252: 363-366.
9. Alexiou C, Tietze R, Schreiber E et al (2010) Pharmakotherapie mittels Nanomedizin: Magnetische Nanopartikel für Hyperthermie und Drug Delivery. Neue Chancen für die Krebsbehandlung. Bundesgesundheitsblatt 53: 839-845.
10. Alexiou C, Tietze R, Schreiber E et al (2011) Cancer therapy with drug loaded magnetic nanoparticles-magnetic drug targeting. J Magn Magn Mater 323: 1404-1407.
11. Bilkenroth U, Taubert H, Riemann D et al (2001) Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. Int J Cancer 92: 577-582.
12. Donaldson K, Murphy FA, Duffin R et al (2010) Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 7: 5.
13. Dürr S, Lyer S, Mann J et al (2012) Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles. Anticancer Res 32: 1983-1990.
14. Dürr S, Tietze R, Lyer S et al (2012) Nanomedicine in otorhinolaryngology-future prospects. Laryngorhinootologie 91: 6-12.
15. Gao Y (2005) Biofunctionalization of magnetic nanoparticles. In: Kumar C (Hrsg) Biofunctionalization of nanomaterials. Wiley-VCH, Weinheim, S 72-98.
16. Grodzinski P (2007) The Workings of NCI Nanotechnology Alliance for Cancer-an Opportunity for a new class of diagnostic and therapeutic solutions based on nanotechnology. http://ion. chem. usu. edu/~tapaskar/piotr. pdf (Zugegriffen: 23. Mai 2012).
17. Harisinghani MG, Barentsz J, Hahn PF et al (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348: 2491-2499.
18. Hodenius M (2002) Polymer- und liposomstabilisierte Ferrofluide und ihre Funktionalisierung. PhD thesis, Fakultät für Mathematik, Informatik und Naturwissenschaften RWTH Aachen.
19. Jurgons R, Seliger C, Hilpert A et al (2006) Drug loaded magnetic nanoparticles for cancer therapy. J Phys Condens Matter 18: 2893-2902.
20. Lauterwasser C (2005), Small sizes that matter: opportunities and risks of nanotechnologies, OECD/Allianz Group, München.
21. Lyer S, Tietze R, Jurgons R et al (2010) Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles-a pilot study. Anticancer Res 30: 1553-1558.
22. Maier-Hauff K, Ulrich F, Nestler D et al (2011) Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 103: 317-324.
23. Nauts HC, Fowler GA, Bogatko FH (1953) A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand 276: 1-103.
24. Pankhurst QA, Thanh NTK, Jones SK et al (2009) Progress in applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 42: 224001-224016.
25. Peer D, Karp JM, Hong S et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-760.
26. Perkins WR, Ahmad I, Li X et al (2000) Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds. Int J Pharm 200: 27-39.
27. Rahn H, Gomez-Morilla I, Jurgons R et al (2008) Microcomputed tomography analysis of ferrofluids used for cancer treatment. J Phys Condens Matter 20: 204152-204156.
28. Richter H, Wiekhorst F, Schwarz K et al (2009) Magnetrelaxometric quantification of magnetic nanoparticles in an artery model after ex vivo magnetic drug targeting. Phys Med Biol 54: N417-424.
29. Seliger C, Jurgons R, Wiekhorst F et al (2007) In vitro investigation of the behaviour of magnetic particles by a circulating artery model. J Magn Magn Mater 311: 358-362.
30. Shimizu K, Ito A, Yoshida T et al (2007) Bone tissue engineering with human mesenchymal stem cell sheets constructed using magnetite nanoparticles and magnetic force. J Biomed Mater Res B Appl Biomater 82: 471-480.
31. Storm G, Belliot SO, Daemen T et al (1995) Surface modifi cation of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17: 31-48.
32. Tietze R, Jurgons R, Lyer S et al (2009) Quantification of drug-loaded magnetic nanoparticles in rabbit liver and tumor after in vivo administration. J Magn Magn Mater 321: 1465-1468.
33. Tietze R, Lyer S, Dürr S et al (2012) Nanoparticles for cancer therapy using magnetic forces. Nanomedicine 7: 447-457.
34. Tietze R, Lyer S, Schreiber E et al (2011) Local cancer therapy with magnetic nanoparticles. In: Alexiou C (Hrsg) Nanomedicine-Basic and clinical applications in diagnostics and therapy. Else Kröner-Fresenius Symp, Bd 2. Karger, Basel, S 154-163.
35. Tietze R, Rahn H, Lyer S et al (2011) Visualization of superparamagnetic nanoparticles in vascular tissue using μCT and histology. Histochem Cell Biol 135: 153-158.
36. Tietze R, Schreiber E, Lyer S et al (2010) Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: a versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV. J Biomed Biotechnol 597304.
37. Wagner V, Dullaart A, Bock AK et al (2006) The emerging nanomedicine landscape. Nat Biotechnol 24: 1211-1217.
38. Wiekhorst F, Jurgons R, Steinhoff U et al (2006) Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting. J Nanosci Nanotechnol 6: 3222-3225.
39. Gleich B, Hellwig N, Bridell H et al (2007) Design and evaluation of magnetic fields for nanoparticle drug targeting in cancer. IEEE Trans Nanotechnol 6: 164-170.